11,000 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Acquired by Uniting Wealth Partners LLC

Uniting Wealth Partners LLC purchased a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in the fourth quarter, Holdings Channel reports. The fund purchased 11,000 shares of the biopharmaceutical company’s stock, valued at approximately $202,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ACAD. SG Americas Securities LLC increased its stake in ACADIA Pharmaceuticals by 380.3% in the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after purchasing an additional 1,966,607 shares during the period. Norges Bank purchased a new position in shares of ACADIA Pharmaceuticals in the fourth quarter valued at $25,555,000. Great Lakes Advisors LLC acquired a new position in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $9,909,000. Burney Co. purchased a new position in ACADIA Pharmaceuticals during the fourth quarter worth $6,953,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of ACADIA Pharmaceuticals by 61.7% during the 4th quarter. JPMorgan Chase & Co. now owns 713,360 shares of the biopharmaceutical company’s stock worth $13,090,000 after purchasing an additional 272,236 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on ACAD. Morgan Stanley reiterated an “equal weight” rating and issued a $20.00 target price on shares of ACADIA Pharmaceuticals in a report on Friday, March 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. StockNews.com raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $23.93.

ACADIA Pharmaceuticals Trading Up 1.8 %

NASDAQ:ACAD opened at $16.62 on Thursday. The stock has a market cap of $2.77 billion, a P/E ratio of 21.31 and a beta of 0.54. The stock has a 50 day simple moving average of $18.26 and a 200 day simple moving average of $17.05. ACADIA Pharmaceuticals Inc. has a 1-year low of $14.15 and a 1-year high of $20.68.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,171 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total transaction of $54,065.55. Following the transaction, the executive vice president now owns 56,889 shares of the company’s stock, valued at $969,957.45. This trade represents a 5.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the sale, the director now directly owns 17,595 shares of the company’s stock, valued at $320,756.85. This represents a 21.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,433 shares of company stock worth $187,319 over the last quarter. Corporate insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.